Abstract CT214: Paricalcitol addition to chemotherapy in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PINBALL)

帕利骨化醇 胰腺导管腺癌 医学 化疗 肿瘤科 腺癌 内科学 胰腺癌 癌症 钙 继发性甲状旁腺功能亢进 甲状旁腺激素
作者
David Propper,Gayle Jameson,Denise J. Roe,Betsy C. Wertheim,Dan Von Hoff,Erkut Borazanci
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (7_Supplement): CT214-CT214 被引量:2
标识
DOI:10.1158/1538-7445.am2024-ct214
摘要

Abstract Background Vitamin D agonism has been shown in preclinical studies to decrease the production of collagen, decrease myeloid derived suppressor cells, and decrease regulatory T cells in pancreatic ductal adenocarcinoma (PDAC). Paricalcitol is a vitamin D analog used for vitamin D replacement for those with secondary hyperparathyroidism. Two individuals with PDAC who had been developed resistance gemcitabine based combination therapy had shown clinical benefit with the addition of paricalcitol. This clinical study was done to study the effect of adding paricalcitol to individuals with metastatic PDAC receiving gemcitabine based combination therapy (NCT04054362, NCT03415854) . Methods Adults with a histologically- or cytologically-confirmed diagnosis of metastatic PDAC and who were previously untreated were eligible. Individuals received gemcitabine based combination- either gemcitabine plus nab-paclitaxel or gemcitabine plus nab-paclitaxel and cisplatin and had to either demonstrate progressive or stable disease. Paricalcitol was given at a fixed dose of 25 mcg IV three days a week. The combination continued until either disease progression or poor tolerance. The primary objective was to determine the clinical benefit of adding paricalcitol to gemcitabine based combination therapy for metastatic PDAC. Secondary objectives included assessing safety and pharmacodynamic through patient biopsies. Results A total of 34 patients were enrolled across two sites. 16 patients received paricalcitol. The overall response rate was 0% ( CR, PR). Disease control rate at 9 weeks was 21.4% (CR+PR+ SD). PFS upon addition of paricalcitol was 1.6 months. OS upon addition of paricalcitol was 4.8 months. Grade 3/4 AE's attributed to paricalcitol include 13% thrombocytopenia; 19% anemia; 6% transaminitis; 6% pleural effusion; 6% ascites- all grade 3. Conclusions The addition of paricalcitol demonstrated evidence of limited clinical benefit in individuals with metastatic PDAC receiving front-line gemcitabine based therapy. Paricalcitol was generally well tolerated. Tumor analysis is ongoing. Addition studies utilizing prospective treatment of paricalcitol for front line treatment of mPDAC are ongoing (NCT03520790). Trial funding provided by SU2C, CRUK, Lustgarten Foundation, and AACR. Citation Format: David Propper, Gayle Jameson, Denise Roe, Betsy Wertheim, Dan Von Hoff, Erkut H. Borazanci. Paricalcitol addition to chemotherapy in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PINBALL) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT214.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
2秒前
Akim的应助被小资采纳,获得30
3秒前
3秒前
3秒前
4秒前
舒心念寒发布了新的文献求助10
4秒前
5秒前
5秒前
Qi完成签到,获得积分10
5秒前
6秒前
zenghong发布了新的文献求助10
6秒前
云山抹完成签到 ,获得积分20
6秒前
听书予你发布了新的文献求助30
8秒前
策略发布了新的文献求助10
8秒前
梦安发布了新的文献求助10
9秒前
9秒前
星辰大海的应助被zzzzzzzz采纳,获得10
9秒前
9秒前
chi发布了新的文献求助10
10秒前
10秒前
123完成签到,获得积分10
11秒前
独特半山完成签到,获得积分10
12秒前
12秒前
13秒前
科研通AI6.3的应助被lhh7771117采纳,获得10
13秒前
xing_xing的应助被lll采纳,获得40
14秒前
14秒前
14秒前
失物爱发布了新的文献求助10
15秒前
ding的应助被yuan采纳,获得10
15秒前
Jun的应助被forgive采纳,获得10
16秒前
脏脏包发布了新的文献求助10
16秒前
17秒前
茉莉蛋糕完成签到,获得积分20
17秒前
17秒前
17秒前
特独斩完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178048
求助须知:如何正确求助?哪些是违规求助? 9568764
关于积分的说明 21801331
捐赠科研通 7772794
什么是DOI,文献DOI怎么找? 3432613
关于科研通互助平台的介绍 2556748
邀请新用户注册赠送积分活动 2478151